Verici Dx Plc

Verici Dx plc, through its subsidiary Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. Its products include Tutivia, a post-transplant diagnostic test for acute cellular rejection including sub-clinical rejection; Clarava, a pre-transplant prognosis test for early acute rejection risk; and Protega, a liquid biopsy predicting fibrosis and long-term graft failure risk. The company also offers sequencing services for tumor-only, tumor-normal, and germline exomes, whole transcriptome, targeted RNASeq and ncRNAs, and functional binding multicell assays, as well as bioinformatics and data science services. It collaborates with One Lambda Inc. on pre-transplant risk assessment (PTRA), The Westmead Institute for Medical Research on graft loss factors, and FBB Biomed, Inc. on research-use-only tests for neurologic diseases. Incorporated in 2020, Verici Dx plc is headquartered in Cardiff, United Kingdom.